KLDO — Kaleido Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$16.78m
- $1.10m
Annual income statement for Kaleido Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.975 | 1.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 27 | 60.7 | 87.2 | 79.8 | 88.8 |
| Operating Profit | -27 | -60.7 | -87.2 | -78.9 | -87.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.6 | -61.7 | -86.3 | -81.6 | -90.3 |
| Net Income After Taxes | -27.6 | -61.7 | -86.3 | -81.6 | -90.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.6 | -61.7 | -86.3 | -81.6 | -90.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.6 | -61.7 | -86.3 | -81.6 | -90.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.938 | -2.1 | -3.34 | -2.44 | -2.16 |
| Dividends per Share |